Peripheral Neuropathy: Can Regenerative Medicine Restore What Nerve Damage Takes Away?

When damaged nerves leave you with burning, numbness, or weakness in your hands and feet, conventional medicine manages symptoms. Regenerative research is investigating whether nerve function can actually be restored.

The Problem

When You Can't Trust Your Own Feet

Peripheral neuropathy begins insidiously. Perhaps you notice that bathwater feels less hot on your toes. Or a pins-and-needles sensation that doesn't go away. Or an ache in your feet at night that disrupts sleep.

As the condition progresses, the symptoms escalate:

Numbness that creeps up from toes to feet to lower legs (the "stocking-glove" pattern)
Burning pain that conventional painkillers barely touch
Balance impairment — without sensation from your feet, proprioception fails, and falls become a serious risk
Weakness — when motor nerves are affected, muscles waste and feet can drop
Autonomic dysfunction — affected nerves controlling heart rate, blood pressure, and digestion

For the estimated 20 million Americans with peripheral neuropathy1, the condition doesn't just cause pain — it steals independence. Falls become the leading fear. Driving becomes unsafe. Walking becomes treacherous.

The Treatment Gap

The fundamental gap: Nothing in the standard treatment arsenal rebuilds damaged nerve fibres or restores lost sensation. Regenerative medicine research aims to close this gap.

Understanding Peripheral Neuropathy

Illustration showing peripheral nerve anatomy with myelin sheath, axon, and comparison of healthy vs. demyelinated nerve

Types of Peripheral Neuropathy

The Biology of Nerve Damage

Peripheral nerves consist of:

Axons — the long nerve fibres that transmit electrical signals (some extending over 1 metre from spinal cord to toes)
Myelin sheath — the insulating layer (produced by Schwann cells) that enables rapid signal conduction
Endoneurium/perineurium — connective tissue that bundles and protects nerve fibres
Vasa nervorum — tiny blood vessels that supply oxygen and nutrients to the nerve

Neuropathy can involve:

Demyelination — loss of the myelin sheath, slowing signal conduction (treatable; re-myelination possible)
Axonal degeneration — destruction of the nerve fibre itself (more serious; regeneration slow and incomplete)
Wallerian degeneration — complete nerve death distal to injury site (requires full regrowth)

Why Peripheral Nerves Can Regenerate (But Often Don't)

Unlike the brain and spinal cord, peripheral nerves retain the capacity for regeneration:

Schwann cells survive and form "bands of Büngner" — aligned tubes that guide regrowing axons
Growth cone formation — the cut end of an axon forms a growth cone that can navigate toward its target
Regeneration rate: approximately 1-3 mm per day (about 1 inch per month)
Growth factors: NGF, BDNF, GDNF, and NT-3 support regrowth

However, regeneration frequently fails because:

In chronic neuropathy, the supportive Schwann cell environment degrades over time
Endoneurial fibrosis (scarring) obstructs regrowth paths
In metabolic neuropathies (diabetes), ongoing toxic conditions impair regeneration even as it occurs
The regrowth distance from foot to spinal cord is enormous — axons may take 2-3 years to fully regenerate
Target muscle and sensory receptors atrophy during prolonged denervation, reducing re-innervation success

This is where regenerative medicine enters: enhancing the nerve's own regenerative capacity by providing concentrated growth factors, reducing inflammation, and restoring the supportive environment that enables regrowth.

What the Research Says

PRP for Peripheral Neuropathy — Encouraging RCT Evidence

Anjayani et al. (2014) — Randomised Controlled Trial:

An RCT evaluating PRP perineural injection in 60 patients (30 per arm) with leprosy-related peripheral neuropathy3:

Sensory improvement: Significant improvement in two-point discrimination test (TPDT) and VAS pain scores in PRP group vs. control (p < 0.05)
Rapid onset: Improvements documented at 2 weeks post-injection
Safety: No serious adverse events
Note: While this study focused on leprosy neuropathy, the PRP mechanism (growth factor-mediated nerve repair) is applicable across neuropathy types

Hassanien et al. (2020) — PRP for Diabetic Neuropathy RCT:

An RCT of 60 diabetic neuropathy patients randomised to PRP injection vs. standard care5:

Toronto Clinical Scoring System (TCSS): Significant improvement in PRP group (mean decrease 3.8 points vs. 0.4 in control, p < 0.001)
Nerve conduction studies: Improved sural nerve conduction velocity and amplitude
Sustained benefit: Improvements maintained at 6-month follow-up
Mechanism: PRP growth factors (PDGF, VEGF, NGF) stimulate Schwann cell proliferation and axonal regrowth

Sánchez et al. (2017) — PRP for Peripheral Nerve Regeneration (Review):

A comprehensive review of PRP applications in peripheral nerve regeneration, synthesising evidence from preclinical and clinical studies6:

Growth factor delivery: PRP provides concentrated NGF, BDNF, VEGF, and PDGF that support Schwann cell proliferation and axonal regrowth
Clinical applications: Evidence reviewed for compressive, traumatic, and metabolic neuropathies
Applicability: Supports the rationale for PRP across multiple neuropathy types beyond diabetic neuropathy specifically

MSC Therapy — Phase I/II Data

Hur et al. (2016) — Allogeneic Placenta-Derived MSCs for Diabetic Neuropathy:

A Phase I/IIa trial of allogeneic placenta-derived MSCs in 10 patients with diabetic peripheral neuropathy4:

Safety: Well-tolerated with no serious cell-related adverse events at 12 months
Nerve conduction improvement: Significant improvement in tibial motor NCV and sural sensory NCV at 12 months
Symptom scores: Improvement in Michigan Neuropathy Screening Instrument (MNSI) scores
Pain reduction: Significant decrease in visual analogue scale (VAS) pain scores
Skin biopsy: Increased intraepidermal nerve fibre density (IENFD) in 2 of 3 biopsied patients — suggesting actual nerve fibre regeneration

Significance: The increase in IENFD is particularly notable because it represents objective evidence of nerve fibre regrowth — not just symptom management.

Mao et al. (2019) — Autologous BM-MNC for Diabetic Neuropathy:

A study of 168 patients with refractory diabetic peripheral neuropathy treated with intramuscular bone marrow mononuclear cell transplantation7:

Toronto Clinical Scoring System: Improved from 12.55 to 9.68 at 1 month (p < 0.001), sustained through 36-month follow-up
Motor NCV: Improved from 38.21 to 40.24-41.00 m/s (p < 0.001)
Sensory NCV and action potentials: Also improved significantly at 3 and 12 months
Safety: No treatment-associated adverse events

Growth Factor-Based Approaches

Apfel et al. (2000) — Recombinant NGF for Diabetic Neuropathy:

A Phase III RCT of subcutaneous recombinant human nerve growth factor (rhNGF) in 1,019 patients8:

Primary endpoint (Neuropathy Impairment Score): Not statistically significant vs. placebo
However: Significant improvement in Neuropathy Total Symptom Score and patient global assessment
Key finding: Exogenous NGF improved symptoms but failed to demonstrate objective nerve regeneration at the doses and route used
Significance: The concept of growth factor supplementation remains valid; PRP and MSCs deliver a more comprehensive cocktail of factors and may succeed where single-factor approaches have not

Summary Table

Treatment Approach at Our Clinic

Our Neuropathy Protocol

Candidacy

Best candidates:

Diabetic peripheral neuropathy with documented nerve conduction impairment
Idiopathic small-fibre neuropathy — unexplained burning pain in hands and feet
Chemotherapy-induced peripheral neuropathy (CIPN) — post-treatment nerve damage
Non-diabetic metabolic neuropathies (B12 deficiency, hypothyroid — once underlying cause corrected)
Compressive neuropathies insufficiently responsive to standard treatment

Important considerations:

Underlying cause must be identified and managed (continued uncontrolled diabetes will undermine regenerative benefit)
Severe long-standing neuropathy with complete axonal loss has lower regenerative potential
Hereditary neuropathies (Charcot-Marie-Tooth) — structural genetic conditions; regenerative approaches may support but cannot correct the genetic defect
Active autoimmune neuropathy (CIDP, GBS) should be managed with immunotherapy before considering regenerative approaches

What to Expect: Our 7-Day Protocol

Day 1-2: Diagnostic Assessment

Detailed neurological examination with neuropathy severity grading
Nerve conduction studies (NCS) and electromyography (EMG)
Quantitative sensory testing for small-fibre assessment
Blood panel: HbA1c, B12, folate, thyroid function, inflammatory markers, heavy metals
Discussion of diagnosis, prognosis, and realistic treatment expectations

Day 3-5: Treatment Phase

PRP preparation and ultrasound-guided perineural injection (targeting affected nerve courses)
IV NAD+ infusion (mitochondrial support for nerve energy metabolism)
IV neurotrophic and anti-inflammatory protocols
Balance and proprioceptive physiotherapy initiation
Nutritional counselling for nerve health

Day 6-7: Planning & Follow-Up

Review treatment response and expected timeline
Home exercise programme for balance and lower limb strength
Supplement and nutritional plan for nerve support
Follow-up schedule: 6-week, 3-month, 6-month nerve conduction reassessment
Planning for additional PRP sessions if indicated (typically 3 sessions total)

Recovery Expectations

Frequently Asked Questions

Q: Can peripheral neuropathy actually be reversed?

A: This depends on the type and severity. Demyelinating neuropathy (where the insulation around nerves is damaged but the nerve fibre itself is intact) has the best potential for recovery, as Schwann cells can re-myelinate nerve fibres. Mild-to-moderate axonal neuropathy can partially regenerate — peripheral nerves have this capacity, unlike central nerves. Severe, long-standing neuropathy with complete axonal loss and target organ atrophy has the lowest regenerative potential. Clinical trials with PRP and MSCs have shown measurable nerve conduction improvements, suggesting actual nerve repair34.

Q: My neuropathy isn't from diabetes — does this research still apply?

A: Yes. While most clinical trials have focused on diabetic peripheral neuropathy (because it's the most common form), the nerve biology of regeneration is the same regardless of cause. PRP and MSC growth factors support nerve repair through universal mechanisms (Schwann cell activation, axonal regrowth, angiogenesis). Early studies in non-diabetic neuropathies show similar promise6. The critical factor is addressing the original cause alongside regenerative treatment.

Q: How long does nerve regeneration take?

A: Peripheral nerves regenerate at approximately 1-3 mm per day — about 1 inch per month. For neuropathy affecting the feet, the regenerating nerve fibres may need to travel a considerable distance from the lower leg. This means meaningful recovery typically takes 6-12 months, with continued improvement possible up to 24 months. This is why patience and consistent follow-up are essential.

Q: I've been told nothing can be done for my neuropathy — is that true?

A: The statement that "nothing can be done" typically means that conventional treatments cannot reverse nerve damage — which is accurate for current standard therapies. However, the emerging regenerative evidence suggests that enhancing the nerve's natural repair capacity may be possible. While this research is still developing, the PRP evidence in particular shows measurable nerve conduction improvements in controlled trials. A thorough assessment can determine whether your specific type and severity of neuropathy might benefit from these approaches.

Q: What about chemotherapy-induced neuropathy (CIPN)?

A: CIPN is a significant problem affecting 30-40% of patients receiving neurotoxic chemotherapy (taxanes, platinum compounds, vinca alkaloids). Research on regenerative approaches for CIPN is early but the mechanism is promising — chemotherapy damages nerve fibres, but the supportive architecture (Schwann cells, endoneurium) often remains intact, providing a framework for regeneration. PRP growth factors may help accelerate the nerve recovery that can occur naturally after chemotherapy completion.

Take the Next Step

Living with neuropathy? Want to know if regenerative treatment might help your situation?

Take our 2-minute Health Assessment to tell us about your symptoms
Book a Discovery Consultation to discuss your neuropathy with our specialist team

Your nerves have the capacity to heal. The question is whether we can help them do it faster and more completely.